Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity
- PMID:16344479
- PMCID: PMC1311737
- DOI: 10.1073/pnas.0508254102
Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity
Abstract
Apolipoprotein (apo) E4, a 299-aa protein and a major risk factor for Alzheimer's disease, can be cleaved to generate C-terminal-truncated fragments that cause neurotoxicity in vitro and neurodegeneration and behavioral deficits in transgenic mice. To investigate this neurotoxicity, we expressed apoE4 with C- or N-terminal truncations or mutations in transfected Neuro-2a cells. ApoE4 (1-272) was neurotoxic, but full-length apoE4(1-299) and apoE4(1-240) were not, suggesting that the lipid-binding region (amino acids 241-272) mediates the neurotoxicity and that amino acids 273-299 are protective. A quadruple mutation in the lipid-binding region (I250A, F257A, W264R, and V269A) abolished the neurotoxicity of apoE4(1-272), and single mutations in the region of amino acids 273-299 (L279Q, K282A, or Q284A) made full-length apoE4 neurotoxic. Immunofluorescence staining showed that apoE4(1-272) formed filamentous inclusions containing phosphorylated tau in some cells and interacted with mitochondria in others, leading to mitochondrial dysfunction as determined by MitoTracker staining and flow cytometry. ApoE4(241-272) did not cause mitochondrial dysfunction or neurotoxicity, suggesting that the lipid-binding region alone is insufficient for neurotoxicity. Truncation of N-terminal sequences (amino acids 1-170) containing the receptor-binding region (amino acids 135-150) and triple mutations within that region (R142A, K146A, and R147A) abolished the mitochondrial interaction and neurotoxicity of apoE4(1-272). Further analysis showed that the receptor-binding region is required for escape from the secretory pathway and that the lipid-binding region mediates mitochondrial interaction. Thus, the lipid- and receptor-binding regions in apoE4 fragments act together to cause mitochondrial dysfunction and neurotoxicity, which may be important in Alzheimer's disease pathogenesis.
Figures





Similar articles
- Effect of carboxyl-terminal truncation on structure and lipid interaction of human apolipoprotein E4.Tanaka M, Vedhachalam C, Sakamoto T, Dhanasekaran P, Phillips MC, Lund-Katz S, Saito H.Tanaka M, et al.Biochemistry. 2006 Apr 4;45(13):4240-7. doi: 10.1021/bi060023b.Biochemistry. 2006.PMID:16566598
- Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease.Chen HK, Ji ZS, Dodson SE, Miranda RD, Rosenblum CI, Reynolds IJ, Freedman SB, Weisgraber KH, Huang Y, Mahley RW.Chen HK, et al.J Biol Chem. 2011 Feb 18;286(7):5215-21. doi: 10.1074/jbc.M110.151084. Epub 2010 Nov 30.J Biol Chem. 2011.PMID:21118811Free PMC article.
- Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease.Huang Y.Huang Y.Trends Mol Med. 2010 Jun;16(6):287-94. doi: 10.1016/j.molmed.2010.04.004. Epub 2010 May 27.Trends Mol Med. 2010.PMID:20537952Review.
- Amyloid-peptide β 42 Enhances the Oligomerization and Neurotoxicity of apoE4: The C-terminal Residues Leu279, Lys282 and Gln284 Modulate the Structural and Functional Properties of apoE4.Dafnis I, Argyri L, Chroni A.Dafnis I, et al.Neuroscience. 2018 Dec 1;394:144-155. doi: 10.1016/j.neuroscience.2018.10.026. Epub 2018 Oct 24.Neuroscience. 2018.PMID:30367942
- Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies.Huang Y.Huang Y.Curr Opin Drug Discov Devel. 2006 Sep;9(5):627-41.Curr Opin Drug Discov Devel. 2006.PMID:17002223Review.
Cited by
- Exploratory analysis of mtDNA haplogroups in two Alzheimer's longitudinal cohorts.Swerdlow RH, Hui D, Chalise P, Sharma P, Wang X, Andrews SJ, Pa J, Mahnken JD, Morris J, Wilkins HM, Burns JM, Michaelis ML, Michaelis EK; Alzheimer's Disease Neuroimaging Initiative (ADNI).Swerdlow RH, et al.Alzheimers Dement. 2020 Aug;16(8):1164-1172. doi: 10.1002/alz.12119. Epub 2020 Jun 16.Alzheimers Dement. 2020.PMID:32543785Free PMC article.
- APOE traffics to astrocyte lipid droplets and modulates triglyceride saturation and droplet size.Windham IA, Powers AE, Ragusa JV, Wallace ED, Zanellati MC, Williams VH, Wagner CH, White KK, Cohen S.Windham IA, et al.J Cell Biol. 2024 Apr 1;223(4):e202305003. doi: 10.1083/jcb.202305003. Epub 2024 Feb 9.J Cell Biol. 2024.PMID:38334983Free PMC article.
- Full-length apolipoprotein E protects against the neurotoxicity of an apoE-related peptide.Crutcher KA, Lilley HN, Anthony SR, Zhou W, Narayanaswami V.Crutcher KA, et al.Brain Res. 2010 Jan 8;1306:106-15. doi: 10.1016/j.brainres.2009.10.021. Epub 2009 Oct 21.Brain Res. 2010.PMID:19836363Free PMC article.
- Pathogenesis of Alzheimer's disease.Swerdlow RH.Swerdlow RH.Clin Interv Aging. 2007;2(3):347-59.Clin Interv Aging. 2007.PMID:18044185Free PMC article.Review.
- Invited Review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer's disease.Tzioras M, Davies C, Newman A, Jackson R, Spires-Jones T.Tzioras M, et al.Neuropathol Appl Neurobiol. 2019 Jun;45(4):327-346. doi: 10.1111/nan.12529. Epub 2018 Nov 28.Neuropathol Appl Neurobiol. 2019.PMID:30394574Free PMC article.Review.
References
- Mahley, R. W. (1988) Science 240, 622-630. - PubMed
- Mahley, R. W. & Huang, Y. (1999) Curr. Opin. Lipidol. 10, 207-217. - PubMed
- Huang, Y. & Mahley, R. W. (1999) in Plasma Lipids and Their Role in Disease, eds. Barter, P. J. & Rye, K.-A. (Harwood, Amsterdam), pp. 257-284.
- Mahley, R. W. & Rall, S. C., Jr., (2000) Annu. Rev. Genomics Hum. Genet. 1, 507-537. - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources